EI
MXCT icon

Ellevest Inc’s MaxCyte MXCT Stock Holding History

Ellevest Inc’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-19
Closed – – 1575
2022
Q1 		$0 Buy
+19
New +$130 ﹤0.01% 1553

Other funds holding MXCT

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RGI
River Global Investors London, United Kingdom $515M AUM 24.86% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Ellevest Inc's MXCT Position: Q2 2022 in Review

Ellevest Inc sold out of MaxCyte (MXCT) in Q2 2022, closing a stake of 19 shares.

Ellevest Inc first reported a position in MXCT in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 102 funds tracked by Wall St. Rank hold MXCT as of Q2 2022.

  • Ellevest Inc reported no remaining MaxCyte position as of Q2 2022 after selling out during the quarter.
  • Ellevest Inc sold 19 MaxCyte shares in Q2 2022.
  • Ellevest Inc first reported a position in MaxCyte in Q1 2022 and held it in 1 quarter.
  • Ellevest Inc's MaxCyte position peaked at $0 in Q1 2022.
  • 102 funds tracked by Wall St. Rank held MaxCyte as of Q2 2022.

Based on Ellevest Inc's 13F filing for Q2 2022, filed 18 Jul 2022.